8-K: Atara Biotherapeutics Reports Positive Clinical Progress and Financial Update, Securing Cash Runway into 2027

Atara Biotherapeutics announced its fourth quarter and full year 2023 financial results, highlighted by progress in its allogeneic CAR T pipeline and a positive pre-BLA meeting for tab-cel, extending its cash runway into 2027.

Summary

• Atara Biotherapeutics reported its financial results for the fourth quarter and full year 2023, alongside operational progress.
• The company is advancing its allogeneic CAR T therapy programs, including ATA3219 for lupus nephritis and non-Hodgkin's lymphoma.
• A Biologics License Application (BLA) for tab-cel is on track for submission in the second quarter of 2024.
• Atara has expanded its global partnership with Pierre Fabre Laboratories for tab-cel, receiving $27 million upfront and potentially up to $640 million in additional payments.
• The company expects to receive $20 million in regulatory milestones in April 2024, with another $20 million upon BLA acceptance.
• Atara's cash, cash equivalents, and short-term investments totaled $51.7 million as of December 31, 2023, but pro-forma cash is approximately $104 million when including recent funding.
• Net cash used in operating activities was $50.4 million for the fourth quarter and $193.0 million for the full year 2023.
• The company reported net losses of $60.5 million for the fourth quarter and $276.1 million for the full year 2023.
• Atara anticipates a 35% reduction in full-year 2024 operating expenses compared to 2023.
• The company's cash runway is projected to extend into 2027 due to recent funding and anticipated payments.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant clinical and financial progress, including a positive pre-BLA meeting, a major partnership, and an extended cash runway. While there are financial losses and workforce reductions, the overall tone is optimistic due to the company's strategic advancements and future prospects.

Positives

• The positive pre-BLA meeting with the FDA for tab-cel supports the planned BLA submission in Q2 2024.
• The expansion of the allogeneic CAR T pipeline into autoimmune diseases opens new therapeutic avenues.
• The partnership with Pierre Fabre Laboratories provides significant financial resources and potential future revenue.
• The company's cash runway extending into 2027 provides financial stability for ongoing research and development.
• The clinical data for tab-cel shows strong efficacy with a 51.2% objective response rate in the ALLELE study and 77.8% in the EBVision trial.
• The company is actively enrolling patients in the ATA3219 NHL study, with initial data expected in Q4 2024.
• Preclinical data for ATA3219 and ATA3431 show promising results in terms of persistence and anti-tumor activity.

Negatives

• Atara reported a net loss of $60.5 million for the fourth quarter and $276.1 million for the full year 2023.
• The company's cash balance decreased from $242.8 million at the end of 2022 to $51.7 million at the end of 2023.
• Net cash used in operating activities was $50.4 million for the fourth quarter and $193.0 million for the full year 2023.
• The company has undergone two rounds of workforce reductions, reducing headcount by approximately 30% in November 2023 and an additional 25% in January 2024.

Risks

• The company's financial performance is subject to risks and uncertainties associated with pharmaceutical product development.
• The COVID-19 pandemic and geopolitical events may impact the company's business, research, and clinical development plans.
• The company's cash resources may not be sufficient, requiring additional capital raises.
• Clinical trial outcomes are uncertain, and there is a risk that product candidates may not be successful.
• The company is dependent on the success of its partnership with Pierre Fabre Laboratories for tab-cel.

Future Outlook

Atara expects its cash runway to extend into 2027, supported by recent funding, anticipated milestone payments, and reduced operating expenses. The company plans to submit the tab-cel BLA in Q2 2024 and advance its allogeneic CAR T programs, including ATA3219 and ATA3431.

Management Comments

• Pascal Touchon, President and Chief Executive Officer of Atara, stated that they are expanding Atara's proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease.
• Pascal Touchon highlighted the strong momentum for the lead CAR T program, ATA3219, which is positioned to deliver near-term clinical data for both non-Hodgkins lymphoma and lupus nephritis.
• Pascal Touchon also mentioned the focus on submitting the BLA for tab-cel in the second quarter, which triggers financial milestones and sales royalty opportunities in the partnership with Pierre Fabre.

Industry Context

Atara's focus on allogeneic CAR T therapy aligns with the industry trend towards off-the-shelf cell therapies, which offer advantages over autologous therapies in terms of cost, scalability, and accessibility. The expansion into autoimmune diseases also reflects a growing interest in using cell therapies beyond oncology. The partnership with Pierre Fabre is a significant step for Atara, as it provides financial resources and validation of its technology.

Comparison to Industry Standards

• Atara's 51.2% objective response rate (ORR) in the Phase 3 ALLELE study for tab-cel is competitive with other cell therapies for relapsed or refractory EBV+ PTLD.
• The 77.8% ORR in the Phase 2 EBVision trial for CNS EBV+ PTLD is a strong result, indicating potential for this therapy in a difficult-to-treat patient population.
• The expansion of Atara's allogeneic CAR T platform into autoimmune diseases is a novel approach, as most CAR T therapies are currently focused on oncology.
• The company's cash runway into 2027 is a positive sign, as many biotech companies face challenges in securing long-term funding.
• The 35% reduction in operating expenses is a significant step towards financial sustainability, which is important for long-term success.

Related Party Transactions

• The expanded global partnership with Pierre Fabre Laboratories is a related party transaction.

Stakeholder Impact

• Shareholders will benefit from the extended cash runway and potential future revenue from the Pierre Fabre partnership.
• Employees have been impacted by the workforce reductions, but the company's long-term prospects may provide future opportunities.
• Patients with cancer and autoimmune diseases may benefit from the development of new therapies.
• The partnership with Pierre Fabre may provide access to a broader market for tab-cel.

Next Steps

• Submit the tab-cel BLA in Q2 2024.
• Initiate a Phase 1 lupus nephritis study for ATA3219 in H2 2024.
• Continue enrollment in the ATA3219 NHL study.
• Advance the development of ATA3431 towards an IND submission in 2025.
• Transition substantially all activities relating to tab-cel to Pierre Fabre at the time of the BLA transfer.

Key Dates

Keywords

Atara Biotherapeutics, T-cell immunotherapy, allogeneic CAR T, tab-cel, ATA3219, ATA3431, lupus nephritis, non-Hodgkins lymphoma, BLA, Epstein-Barr virus, EBV, Pierre Fabre Laboratories, clinical trials, regulatory milestones